Latest Capital Markets News

Elementos Limited advances its Oropesa and Cleveland tin projects with a strategic smelter acquisition and a $9.1 million capital raise, positioning itself strongly amid rising tin prices.

Cobalt Blue Holdings has enhanced the financial outlook for its Kwinana Cobalt Refinery project, secured a $5.3 million capital raise, and advanced key environmental and feedstock initiatives amid a tightening cobalt market.

4DMedical has rapidly commercialised its CT – VQ™ lung imaging technology following FDA clearance, securing major partnerships and regulatory approvals that position it for significant growth in North America.

Ioneer Ltd has raised US$50 million through a share placement to accelerate development of its Rhyolite Ridge Lithium-Boron Project, positioning itself as a key U.S. supplier of critical minerals.

Atomic Eagle Limited has announced a substantial uranium exploration target at its Muntanga Project in Zambia, supported by promising drilling results that suggest significant resource expansion potential.

Kairos Minerals wraps up its largest drilling campaign at Mt York, revealing promising gold zones and signing a key mining agreement with the Nyamal people, while gearing up for a resource update and further exploration.

Medallion Metals has completed a pivotal feasibility study for its Ravensthorpe Gold Project and raised $60 million to accelerate development, while progressing a key acquisition of Forrestania assets.

US1 Critical Minerals reports ongoing legal disputes over US rare earth tenements while advancing Tanzanian uranium exploration and securing $1.5 million in new capital.

Green360 Technologies has made significant strides in commercialising its low-carbon cement product Eco-Clay, delivering successful large-scale trials and securing a robust financial footing heading into 2026.

Locksley Resources has made significant strides at its Mojave Project, advancing drilling, securing major US institutional funding, and forging key partnerships to establish a domestic supply chain for critical antimony and rare earth elements.

Vital Metals has raised A$12.47 million in the second half of 2025 to fund its Tardiff Pre-Feasibility Study, underpinning the development of its high-grade rare earths project in Canada. The strong investor backing follows a robust July 2025 Scoping Study highlighting significant economic potential.

Neurizon Therapeutics has cleared a major regulatory hurdle with the FDA lifting the clinical hold on its lead drug NUZ-001 and secured a comprehensive $33 million funding package to advance its pivotal ALS trial.